All 17 founding health systems have chipped into the health data platform developer’s series A round, which closed with contributions from three new members.

Electric aircraft developer Heart Aerospace raised $35m from investors including Mesa Air and United, while several corporates are set to exit remote access software developer Openpath.

GV has contributed to two rounds for the gene-editing technology developer, which publicly launched yesterday with $315m of funding.

Lilly Asia Ventures co-led a series A round for ProfoundBio that will help it develop its novel technology and targeted cancer therapeutics.

Lilith Games helped artificial intelligence software developer Inspir.ai secure $46.3m while Microsoft AI spinoff Xiaoice closed its series A round at a billion-dollar valuation.

Munich Re and Microsoft helped CO2-to-chemicals technology provider Twelve raise $57m while Eli Lilly and Kaiser Permanente-backed CRO dMed-Clinipac secured $50m.

The precision oncology platform is based on research by Duke and Hubrecht Institute faculty and the cash will fund technology development and clinical studies.

GV contributed to the precision oncology platform developer's series A round, which will fund technology development and clinical studies.

Novo and Sanofi Ventures both participated in a series A round for the neurodegenrative disease drug developer, which is led by EIRs at Novo Seeds.

The musculoskeletal healthcare provider has added cash from Intermountain Healthcare, Ascension Ventures and Echo Health Ventures to a round now surpassing $50m.